• GT Biopharma reported a net loss of about $2.8 million for second-quarter 2026, widening from about $800,000 a year earlier.
• Operating loss widened to about $2.8 million from about $1.9 million, as SG&A expenses climbed to about $2.4 million from about $800,000 on higher marketing expenses and, to a lesser extent, legal fees.
• R&D expense fell to about $400,000 from about $1.1 million on lower production costs.
• Cash and cash equivalents totaled about $9 million as of March 31, 2026, expected to fund operations through Q4 2026.
• Phase 1 GTB-3650 dose-escalation trial had treated 8 patients across four cohorts, while Phase 1 basket trial for GTB-5550 in B7-H3 solid tumors launched in May 2026 with updates expected in 2H 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GT Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605150800PRIMZONEFULLFEED9721178) on May 15, 2026, and is solely responsible for the information contained therein.